LegoChem Biosciences has teamed up with Novimmune to develop and test antibody drug conjugate (ADC) drug.
TxCell has raised €11m through a share issue which it will use to fund first-in-man study of one of its cell therapy candidates.
Ohr Pharmaceutical Inc. has halted activities at the laboratory in San Diego, California where research on its sustained release delivery technology was carried out.
The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.
Celyad SA has enrolled the first multiple myeloma patient in a safety and tolerability trial of its CAR-T therapy.
Vaccines do not cause autism and people who say otherwise are wrong.
Cambridge Research Biochemicals (CRB) has launched a second catalogue of research antibodies for academia, pharma and outsourcing firms.